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Hypertension is very prevalent among patients undergoing dialysis therapy: hemodialysis (HD) and peritoneal dialysis
(PD). Although it is recognized as a great risk of cardiovascular mortality for these populations, how to regulate blood
pressure (BP) is poorly understood. For HD patients, we should pay much attention to methods of measuring BP. Out-
of-center BP levels and BP variability should be evaluated by ambulatory BP monitoring and home BP measurement
because they are closely associated with cardiovascular mortality. Although target BP levels are not clear, several clinical
guidelines suggest <140/90 mmHg. However, it must be determined for each individual patient with careful
considerations about comorbidities. Based on the underling pathophysiology of hypertension in patients on dialysis,
maintaining an appropriate volume of body fluid by dietary salt restriction and optimization of dry weigh should be
considered as a first line therapy. Inhibitors for renin-angiotensin system may be suitable to reduce BP and mortality for
those patients on dialysis. These drugs may also be effective for preserving residual renal function and peritoneal
function for PD patients. β-blockers may have potentials to improve survival for HD patients and can be added to anti-
hypertensive medications. Lacking large-scale and good quality clinical trials, there are many questions to be answered.
Much effort should continuously be made to create evidences for better management of hypertension for patients on
dialysis therapy.
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Hypertension is very prevalent in patients undergoing dia-
lysis therapy [1, 2]. As is for general population, it is one
of the major causes of cardiovascular mortality for those
who take dialysis [3]. It is still challenging to treat hyper-
tension in patients on dialysis because there are many
unsolved problems and concerns for the management of
hypertension, mainly due to few good quality clinical
trials. In this review, these problems will be discussed
according to therapy types of dialysis: hemodialysis (HD)
and peritoneal dialysis (PD).Management of hypertension for patients on HD
Concerns about blood pressure (BP) measurement
It is of note that any standard methods to measure BP
have not yet been established. Most of clinical studies have
used pre-HD BP for determining optimal BP levels orCorrespondence: ytaniya@med.kindai.ac.jp
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ever, there is a great concern about when or how to meas-
ure BP [5]. A major determinant of blood pressure in HD
patients is body fluid volume. Therefore, individual
patient’s BP varies even during an HD session as well as
between sessions [6]. This inconsistence is considered as a
part of reasons why the association of BP levels and clin-
ical outcomes has been controversial. Although conven-
tional BP measurements during HD sessions is certainly
important for the purpose of volume assessment and
safety, we should consider other methods to evaluate pa-
tient’s BP such as ambulatory BP monitoring (ABPM) and
home BP (HBP) measurements. These “out-of-dialysis-
unit” BP measurements have shown to be superior to con-
ventional BP measurements as they are linearly associated
to the mortality of HD patients. For example, in a pro-
spective cohort study, a 44-h ABP recording or 1-week
HBP recording has more predictive power for target organ
damage and mortality than conventional BP recordings
[7]. Thus, it is recommended to measure BP with multipledistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Outcomes Quality Initiative (K/DOQI) and Japanese
Society for Dialysis Therapy (JSDT) [8, 9].
Target BP levels
It has been shown that there is a “U-shape” relationship
between BP and mortality by several observational studies
[10–12] and a prospective cohort study [13], meaning that
BP below certain levels is even more harmful than high
levels. This reverse epidemiology of BP and cardiovascular
mortality makes it difficult to determine target BP levels
when treating hypertension. However, we should be cau-
tious to interpret the results because low BP in these
observational studies does not necessarily mean the con-
sequence of anti-hypertensive treatment. In other words,
patients with severe cardiovascular comorbidities may be
included in those who have low BP, contributing to the
poor prognosis. A multicenter prospective cohort study
has recently reported interesting results about the rela-
tionship between all-cause mortality and systolic BP (SBP)
[14]. In the study, there is a “U-shape” association to “dia-
lysis-unit” SBP. In contrast, “out-of-dialysis-unit” SBP has
a linear association to the mortality. These results sug-
gest that optimal target BP for treatment should be de-
termined by ABPM and HBP, although no such target
has established yet.
As a target, the guidelines such as by K/DOQI and JSDT
recommend BP less than 140/90 mmHg at the beginning
of the week, with a caution not to apply uniformly to all
patients [8, 9]. The caution includes how to reach the tar-
get BP. Aggressive approach to control BP can be a risk of
symptomatic intradialytic hypotension, which is a great
hazard for HD patients [15].
Nonpharmacological management of hypertension
in HD patients
As mentioned earlier, BP in patients on HD depends on
the volume of body fluid. Sodium and volume excess is
the most important cause of hypertension. They are often
observed when patients have low adherence to restrict
dietary salt and water. High salt intake has been shown to
associate with high pre-dialysis SBP and cardiovascular
death [16]. It is thus a key to maintain proper body fluid
volume to manage hypertension in HD patients. For this
purpose, providing a patient education to reduce dietary
salt should be the first line therapy. Salt consumption
stimulates osmotic thirst and water drinking, leading to
expand body fluid. Conversely, as far as salt restriction is
successfully achieved, water appetite is minimized. Thus,
guidelines such as by Kidney Disease/Improving Global
Outcomes (KDIGO) and JSDT clearly state the import-
ance of salt restriction [9, 17]. According to these guide-
lines, dietary salt should be restricted to below 5–6 g/day.
Increase in fluid volume can be monitored by bodyweight, and interdialytic weight gain should not exceed
0.8 kg/day.
Another way to regulate the volume of body fluid is to
set an appropriate dry weight (DW) for individual patient.
In the dry-weight reduction in hypertensive hemodialysis
patients (DRIP) trial, DW reduction by 1 kg at 8 weeks re-
sulted in systolic and diastolic BP decrease by 6.6 and
3.3 mmHg, respectively [18]. This study clearly shows that
the reduction of DW is a simple, efficacious, and well-
tolerated maneuver to improve BP control. Despite the
knowledge that to determine an appropriate DW is
important for BP control, it is still challenging and so-
metimes needs “try and error.” Conventional ways to
optimize DW utilize multiple parameters: physical signs of
overhydration such as leg edema, cardio-thoracic ratio by
chest X-ray, concentrations of serum natriuretic peptides,
and so on. The problem is that these parameters are far
from reliable. Recently, methods using bioimpedance ana-
lysis have been focused as reliable ways to estimate hydra-
tion status. Randomized control studies (RCTs) have
demonstrated that optimization of DW by bioimpedance-
guided methods are safe and capable of improving BP
control [19, 20]. Thus, it is worthwhile applying these
methods for DW setting.
Dialysis frequency also matters to BP regulation. The
Frequent Hemodialysis Network Trial has compared the
effect of a six-times-per-week dialysis regimen to the con-
ventional three times weekly regimen [21]. As a result, the
frequent HD significantly reduces BP. Another random-
ized cross-over study has demonstrated that short daily
HD compared to conventional HD requires fewer anti-
hypertensive medications to achieve the same BP [22].
These studies clearly show that frequent HD can improve
BP control.
Hypoxemia by sleep apnea can be a cause of hyperten-
sion. In general population, obstructive sleep apnea (OSA)
is the frequent underlying disease of secondary hyperten-
sion and resistant hypertension [23]. It has been reported
that patients with end-stage renal disease and with severe
OSA are sevenfold more likely to have resistant hyperten-
sion than individuals in general hypertensive population
[24]. Fluid overload is considered as a mechanism contrib-
uting to the pathogenesis of OSA in patients on dialysis
[25]. Whether interventions to OSA can improve BP con-
trol and mortality is to be examined.
Treatment by anti-hypertensive drugs for HD
patients
Most HD patients require anti-hypertensive drugs to
control BP. Almost all patients have past history of hyper-
tension before starting dialysis and have taken multiple
anti-hypertensive medications. It has been reported by sev-
eral cohort studies including JSDT registry [26] and meta-
analyses [27, 28] that BP control by anti-hypertensive drugs
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mal regimen to control BP and to reduce mortality has not
yet been established.
Dihydropyridine calcium channel blockers (CCBs) are
widely used to reduce BP for dialysis patients as well as
general hypertensive population. They are effective for
overhydrated state commonly observed in HD patients
[29]. A randomized study demonstrated that amlodipine
significantly reduced BP for subjects undergoing HD as
compared with placebo [30]. Although there has been
little evidence showing that CCBs reduce mortality, it is
still considerable to add CCBs to anti-hypertensive
medications.
Inhibitors of renin-angiotensin system (RAS) such as
angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) have been widely
used to reduce the cardiovascular mortality for chronic
kidney disease (CKD) population as well as general popu-
lation. As a consequence, most of patients have already
been prescribed these RAS inhibitors before initiating dia-
lysis therapy. Although no large scale RCTs have not yet
been conducted, RAS inhibitors should be continued un-
less adverse effects are obvious. These agents are particu-
larly beneficial for cardiac comorbidities generally seen in
HD patients and have been effective for reducing left
ventricular mass and mortality [31–34].
Hypertension and heart failure (HF) are the conditions
frequently associated with CKD. In the pathophysiology of
both conditions, sympathetic overactivity plays an import-
ant role [35]. With an ability to seize sympathetic activity,
β-blockers may be suitable for treating both hypertension
and HF in CKD [36]. A meta-analysis concluded that
treatment with β-blockers improved all-cause mortality in
patients with CKD and chronic HF [37]. They seem to be
beneficial for HD patients as well. A retrospective cohort
study analyzing the US Renal Data System (USRDS) has
shown that β-blocker use was associated with a lower risk
of new HF and cardiovascular mortality [38]. One pro-
spective cohort study from Japan has also demonstrated
that the use of β-blockers is significantly associated with
reduced risk of mortality in HD patients [39]. Among β-
blockers, there are many differences in pharmacological
characteristics. Very recently, Weir and colleagues have
provided a potentially important viewpoint regarding the
dialyzability of β-blockers. They conducted a retrospective
cohort study and found that “low-dialyzability” β-blockers
are associated with lower mortality as compared with
“high-dialyzability” β-blockers in elder HD patients [40].
Although not analyzed in Weir’s paper, carvedilol is one
such β-blocker with “low-dialyzability.” It is the only β-
blocker with evidence to reduce mortality rate in HD
patients with dilated cardiomyopathy [41]. With these re-
sults, it can be a reasonable option to administrate potent
β-blockers for HD patients to control BP.Considerations for blood pressure variability (BPV)
There have been growing evidences showing that BPV is
closely associated with worse outcomes in patients with
hypertension [42–44]. BPV is also a great threat to pa-
tients on HD because they are always experiencing BP
change in intra- and inter-HD sessions. It has been dem-
onstrated that visit-to-visit BPV is extremely high in HD
patients than non-HD populations and is a strong pre-
dictor for cardiovascular events [45]. Pre-dialysis systolic
BPV is also associated with cardiovascular and all-cause
mortality [46–48]. Not only pre-dialysis BPV but also
intra- and post-dialysis BPV are related to adverse out-
comes. A higher intradialytic BPV is independently associ-
ated with increased cardiovascular and all-cause mortality
[49, 50]. Intradialytic BP rise is also a well-known compli-
cation of HD. Overhydration and activation of RAS and
sympathetic nervous system are thought to underlie in the
pathophysiology of this phenomenon [51]. It has been
shown that an intra- or post-dialysis BP rise has been an
independent predictor for cardiovascular death [52, 53].
Thus, it appears that BPV is a great risk of cardiovascular
mortality for patients on HD. We should pay much atten-
tion not only to absolute BP values but also to pre- and
inter-HD BPV. To detect and evaluate BPV, the import-
ance of ABPM and HBP measurements is emphasized
here again.
It becomes evident that BPV and cardiovascular damage
are closely associated; however, whether there is causal re-
lationship is still unclear. Among anti-hypertensive drugs,
β-blockers or an antiadrenergic drug has been shown to
abolish the excess risk for death and CV events associated
with a high visit-to-visit SBP variability for CKD patients,
not on HD [54]. This result suggests that BPV is indeed a
cause of cardiovascular events and raises a hypothesis that
these classes of drugs are effective to reduce BPV as well
for patients undergoing HD. Nevertheless, clinical studies
aiming to investigate whether any interventions to reduce
BPV improve mortality will be needed.
Management of hypertension in patients on PD
Epidemiology
Hypertension in PD patients is as prevalent as in HD pa-
tients [55]. For BP evaluation, ABPM and HBP measure-
ments are recommended because BP levels measured by
these methods are closely associated with hypertensive
end-organ damage such as left ventricular hypertrophy
[56, 57]. A guideline published recently by International
Society for Peritoneal Dialysis (ISPD) also recommends
HBP measurement at least once a week [58]. As results
from observational studies, relationship between BP and
mortality is complex. One study showed that a SBP below
110 mmHg was associated with a high mortality [59]. An-
other study showed that a high BP was associated with a
low mortality within the first year of PD initiation, then
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been no RCTs to date to determine the optimal BP levels
for PD patients. In the ISPD guideline [58], target BP
below 140/90 mmHg is recommended based on data from
general and CKD populations.
Nonpharmacological management of hypertension
in PD patients
Salt and water excess is the most important determinant
of raising BP in patients on PD [61, 62] as well as HD pa-
tients. It has been reported that hypervolemia evaluated
by a bioimpedance analysis is indeed associated with high
BP [62]. Conversely, dietary salt restriction contributes
greatly to manage hypertension. A Turkish group has re-
ported that a strict salt restriction (~4 g/day) significantly
reduced BP and improved survival of the patients studied
[63, 64]. Thus, as a first line strategy for BP management,
dietary salt restriction is essential. ISPD guideline recom-
mends salt restriction (<5 g/day) for all peritoneal dialysis
patients unless contraindicated or patients show evidence
of volume contraction or hypotension [58].
Considerations for residual renal function and
peritoneal function
Residual renal function (RRF) has been shown to be an in-
dependent predictor for survival in dialysis patients in-
cluding PD [65]. It becomes more difficult to maintain
dialysis adequacy for PD patients as RRF declines. There-
fore, preserving RRF is particularly important for patients
on PD. For the purpose of RRF preservation, some strat-
egies have been reported effective [66]. These include
keeping proper body fluid volume and controlling BP. It
has been widely accepted that RAS inhibition by ACEIs or
ARBs is to be administrated to CKD patients because they
have an ability to retard the rate of renal function loss
[67]. RRF in PD patients can also be protected by these
drugs as demonstrated by randomized clinical trials
[68, 69]. Recently, a review by the Cochrane library
concluded that ACEIs and ARBs have additional bene-
fits of preserving RRF in patients on PD [70].
For patients on PD, peritoneal function is certainly im-
portant. Deterioration of peritoneal function has been
characterized by neoangiogenesis and fibrosis. Among fac-
tors involved in this process, local RAS plays an important
role [71]. All components of RAS can be produced locally
in the peritoneal tissue and stimulate the signals leading
to angiogenesiss and fibrosis [72]. In retrospective cohort
studies, RAS inhibition was associated with the preser-
vation of ultrafiltration and peritoneal transport rate
[73–75], suggesting that administration of ACEIs or
ARBs can be a way to slow the deterioration of periton-
eal function.
As discussed above, RAS inhibition is beneficial for both
preserving RRF and peritoneal function. One retrospectivestudy suggested that use of ACEIs and ARBs improved
the survival of PD patients [76]. Although high-quality
evidence showing RAS inhibition for reduction of mortal-
ity does not exist [77], this strategy can be considered as a
first line medication for hypertension in patients on PD.
Conclusions
Lacking large scale and good quality clinical trials, there
are many questions to be answered. These include optimal
methods to measure BP, target BP levels, appropriate reg-
ulations of body fluid volume, anti-hypertensive drugs to
be used, and so on for patients on dialysis therapy. Cur-
rently, there is no means of treating hypertension with the
best available knowledge, even if it is not perfect. But for
the future, we should continue to make efforts to create
better evidences about management of hypertension for
those people.
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